Vis enkel innførsel

dc.contributor.authorGran, Olga Vikhammer
dc.contributor.authorSmith, Erin N.
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorJensvoll, Hilde
dc.contributor.authorSolomon, Terry
dc.contributor.authorHindberg, Kristian
dc.contributor.authorWilsgaard, Tom
dc.contributor.authorRosendaal, Frits Richard
dc.contributor.authorFrazer, Kelly A.
dc.contributor.authorHansen, John-Bjarne
dc.date.accessioned2017-03-01T10:35:31Z
dc.date.available2017-03-01T10:35:31Z
dc.date.issued2016-09
dc.description.abstractVenous thromboembolism occurs frequently in cancer patients. Two variants in the factor 5 gene (F5), rs6025 encoding for the factor V Leiden mutation R506Q, and rs4524 encoding K858R, have been found to be associated with venous thromboembolism. We assessed the joint effect of active cancer and these two F5 variants on venous thromboembolism risk in a case-cohort study. Cases with a first venous thromboembolism (n=609) and a randomly selected age-weighted cohort (n=1,691) were sampled from the general population in Tromsø, Norway. Venous thromboembolism was classified as cancer-related if it occurred in the period 6 months before to 2 years after a diagnosis of cancer. Active cancer was associated with an 8.9-fold higher risk of venous thromboembolism (95% CI 7.2–10.9). The risk of cancer-related venous thromboembolism was 16.7-fold (95% CI 9.9–28.0) higher in subjects heterozygous for rs6025 compared with non-carriers of this variant without active cancer. In subjects with active cancer the risk of venous thromboembolism was 15.9-fold higher (95% CI 9.1–27.9) in those with one risk allele at rs4524, and 21.1-fold (95% CI 12.4–35.8) higher in those with two risk alleles compared with non-carriers without active cancer. A synergistic interaction was observed between active cancer and factor V Leiden (relative excess risk due to interaction 7.0; 95% CI 0.5–14.4) and rs4524 (relative excess risk due to interaction 15.0; 95% CI 7.5–29.2). The incidence of venous thromboembolism during the initial 6 months following a diagnosis of cancer was particularly high in subjects with risk alleles at these loci. This implies that the combination of cancer and F5 variants synergistically increases venous thromboembolism risk.en_US
dc.description.sponsorshipThe K.G. Jebsen Thrombosis Research and Expertise Center is supported by an independent grant from the K.G. Jebsen foundation.en_US
dc.descriptionSource: <a href=http://dx.doi.org/10.3324/haematol.2016.147405>doi: 10.3324/haematol.2016.147405</a>en_US
dc.identifier.citationGran, O. et al. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica. 2016;101(9):1046-1053en_US
dc.identifier.cristinIDFRIDAID 1381599
dc.identifier.doi10.3324/haematol.2016.147405
dc.identifier.issn0390-6078
dc.identifier.issn1592-8721
dc.identifier.urihttps://hdl.handle.net/10037/10397
dc.language.isoengen_US
dc.publisherFerrata Storti Foundationen_US
dc.relation.journalHaematologica
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titleJoint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolismen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel